<DOC>
	<DOCNO>NCT03066609</DOCNO>
	<brief_summary>The purpose study determine secukinumab effective safe treatment plaque type psoriasis</brief_summary>
	<brief_title>Study Efficacy Safety Secukinumab Subjects With Moderate Severe Chronic Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subjects must give write , sign date informed consent . 2 . Men woman least 18 year age time screen . 3 . Chronic plaquetype psoriasis present least 6 month diagnose Baseline . 4 . Moderate severe psoriasis define Baseline : PASI score 12 great , IGA mod 2011 score 3 great ( base static scale 0 4 ) , Body Surface Area ( BSA ) affect plaquetype psoriasis 10 % great . 5 . Candidate systemic therapy . This define subject moderate severe chronic plaquetype psoriasis inadequately control topical treatment and/or , phototherapy and/or , previous systemic therapy . 1 . Forms psoriasis chronic plaquetype ( e.g. , pustular , erythrodermic guttate psoriasis ) Screening Baseline . 2 . Druginduced psoriasis . 3 . Ongoing use prohibit treatment . 4 . Previous exposure secukinumab ( AIN457 ) biologic drug directly target IL17 IL17 receptor . 5 . Use investigational drug time enrollment , within 5 halflives enrollment , within 30 day expect pharmacodynamic effect return baseline , whichever longer ; longer require local regulation . 6 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Plaque psoriasis , Secukinumab</keyword>
</DOC>